The stock of PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) is now priced at $4.6 and retained to its previous closing price of $4.6. The stock had 206316 contracts set over the past session. PHAS shares’ daily volume is compared to its average trading volume at 705481 shares. However, it has a float of 25.52 million and although its performance was -7.07% over the week, it’s one to watch. PHAS share price recently placing at $4.51 to $4.69. However, some brokerage firms have priced the stock below the average, including one that has called $14.
The shorts are climbing into the PhaseBio Pharmaceuticals, Inc. stock, with the latest data on short interest released on June 15, 2020, showing that short interest numbers in the PHAS shares have risen. Short interest in the stock represents just 8.8% of its float, but the volume has raised by 265762. The volume of shorted shares rised to 2.246 million from 1.981 million shares over the last two weeks. The average intraday trading volume has been 0.526 million shares, which means that days to cover moved to roughly 4.268965.
In the last trading session, PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) dropped by -$0.35 over the week and lost -$0.7 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $14.08. The stock recorded its established 52-week high on 07/01/19.
Since 03/18/20, the stock has traded to a low of $2.6 at 76.92%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 0. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.
Looking at current readings, PhaseBio Pharmaceuticals, Inc.’s two-week RSI is 45.49. This suggests that the stock is neutral at the moment and that PHAS shares’ price movement remains stable. The stochastic readings are equally revealing at 12.16% meaning the PHAS share price is currently in overbought territory.
The technical chart shows that the PHAS stock will likely settle at between $4.69 and $4.78 per share. However, if the stock dips below $4.51, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $4.42.
Currently, the stock is trading in the red of MACD, with a reading of -0.2. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
Analysts at Maxim Group assigned PHAS a rating of Buy in their intiating review released on October 03. William Blair analysts see the stock as a Outperform with a target price of $ in a flash note released to investors on September 11 initiating covering the stock. Needham analysts see the stock as Buy when the analysts initiated the share price coverage on November 13, placing it at $18.
The average rating for the PHAS equity is 1.5 and is currently gathering a bullish momentum. Of 6 analysts tracking PhaseBio Pharmaceuticals, Inc. polled by Reuters, 0 rated PHAS as a hold. The remaining 6 analysts were split evenly. However, the split wasn’t equal as a majority (6) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.